Share

    


Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 21
  • 1
  • 2
  • »
On Tuesday, Aug. 16, President Joe Biden signed the $740 billion Inflation Reduction Act of 2022 into law, delivering on several key aspects of his “Build Back Better” social and environmental agenda.
Medicare prior authorization requirements acts as a barrier to patients accessing necessary services and treatments, thus creating a need for reform.
A $1.5 trillion omnibus spending package for fiscal year 2022 was passed with broad bipartisan support in Congress and signed into law by President Biden on March 15, 2022.
From January 24 to 28, 2022, ACCC co-sponsored Health Care Value Week—a series of virtual events supporting the advancement of value-based care.
As the United States healthcare system moves to value-based and bundled payments under alternative payment models, it is now more important than ever for cancer programs and practices to quantitatively and qualitatively measure to show the value that supportive cancer care services bring to patients.
On Aug. 4, the Centers for Medicare & Medicaid Services (CMS) released its 2021 Hospital Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (PFS) proposed rules.
As we begin 2020 and an election year, drug pricing is center stage in healthcare politics.
On Sept. 27, ACCC provided comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed CY 2020 Outpatient Prospective Payment System (OPPS) and Physician Fee Schedule (PFS) rules.
For nearly 30 years, TOPS has served oncologists and patients in Tennessee. The organization has focused primarily on issues related to the delivery of the highest quality cancer care, while also working to deter threats to the viability of the community practice model.
Calendar year (CY) 2020 begins the transition in the Medicare physician fee schedule (PFS) payment system away from fee-for-service reimbursement, which is affected by the changing conversion factor, to a payment system that is set with potential changes related to budget neutrality.
Drug pricing reform and a thorough analysis of healthcare spending have been the focus of healthcare leadership across the country since early 2018.
Make Your Voice Heard at ACCC Capitol Hill Day BY BLAIR BURNETT Every two years American voters go to the polls to participate in national elections. This fall’s mid-term elections resulted in a major paradigm shift and an entirely different congressional class. With this shake-up in Washington, D.C., new voices are demanding to be heard. Make yours one of them. Each year, in conjunction …
November 26, 2018 The Honorable Gus Bilirakis U.S. House of Representatives 2112 Rayburn House Office Building Washington, DC 20515 The Honorable Ben Ray Lujan U.S. House of Representatives 2231 Rayburn House Office Building Washington, DC 20515 Dear Representative Bilirakis and Representative Lujan, On behalf of the undersigned organizations, representing …
In September 2018, the Association of Community Cancer Centers (ACCC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to both the 2019 Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules. The arrival of autumn signals seasonal changes, but one constant is the policy implications of the proposed Medicare payment rules …
Medicare Advantage Appeal Outcomes and Audit Findings Raise Concerns About Service and Payment Denials (OEI-09-16-00410; 09/18) U.S. Department of Health and Human Services Office of Inspector General Medicare Advantage Appeal Outcomes and Audit Findings Raise Concerns About Service and Payment Denials Daniel R. Levinson Inspector General …
As policymakers seek legislative solutions to the opioid crisis, it is imperative to recognize that broad opioid bills that do not specifically address the issue of different types of pain run the risk of harming our vulnerable cancer patient population in terms of adequately treating cancer-related pain.
All eyes are on Congress in recent months with Affordable Care Act repeal and tax reform, but the real action—and consequential reimbursement decisions for ACCC cancer programs—is happening on the regulatory side.
In August 2015 the Health Resources and Services Administration (HRSA) released its much-anticipated “mega-guidance” on the 340B Drug Pricing Program, proposing new limits on the program but stopping short of a complete overhaul, prompting mixed reviews from stakeholders.
The last few months have brought big changes to Washington, D.C. The 2014 midterm elections dealt a sweeping victory to Republicans in Congress, giving the party a 54-seat majority in the Senate and its biggest majority in the House since 1928.
While the 340B Program has grown, and reform has been widely debated by policymakers over the past decade, CMS’ rule proposes to fundamentally alter the program (notably a program that is not within CMS’ purview).
    Displaying results 1 - 20 of 21
  • 1
  • 2
  • »